A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
PPI-383 is an antiviral agent (an inhibitor of the hepatitis C virus NS5B polymerase) that is
being developed as a potential treatment for hepatitis C virus infection. This study is being
done to assess the dose-related safety and tolerance of PPI-383 when given to healthy
volunteers for up to 5 days (Part I of the study) and to hepatitis C patients for up to 3
days (Part II). In addition, the study will assess how much PPI-383 is absorbed into the
bloodstream. In Part II, the dose-related effect of PPI-383 on the amount of hepatitis C
virus in patients' bloodstream (serum HCV RNA levels) also will be assessed.